Polatuzumab combo for B-cell lymphomaApril 9, 2019
Polatuzumab vedotin in combination with bendamustine plus rituximab (BR) has been granted priority review by the US FDA for the treatment of people with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
The GO29365, a global, phase Ib/II randomized study, showed that polatuzumab vedotin plus BR improved median overall survival compared to BR alone in people with R/R DLBCL not eligible for a hematopoietic stem cell transplant. The study also showed that 40 percent of people treated with polatuzumab vedotin plus BR achieved a complete response (CR), while only 18 percent of people treated with BR alone achieved a CR.
Polatuzumab is developed by Genentech, a member of the Roche Group.